Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Exp Dent Res ; 9(6): 1169-1179, 2023 12.
Article in English | MEDLINE | ID: mdl-37803883

ABSTRACT

OBJECTIVES: Human papillomavirus (HPV) is associated with 70% of oropharyngeal squamous cell carcinomas. Coronavirus disease 2019 (COVID-19) is the infectious cause of a global pandemic that killed millions worldwide. Effective vaccinations exist against both diseases, but patient acceptance remains a challenge. The objective of this study was to assess patients' attitudes toward oral healthcare providers' (OHCPs) roles in HPV and COVID-19 vaccinations. METHODS: A cross-sectional survey of young adult patients was distributed in Philadelphia, PA, between April and June 2021. The survey assessed knowledge and attitudes around OHCPs serving various roles in COVID-19 and HPV vaccination. RESULTS: Nearly 70% of 163 respondents would accept the recommendation for a COVID-19 vaccine from an OHCP, while 56% would for HPV. Those previously vaccinated against COVID-19 were more comfortable discussing COVID-19 vaccines (92%, p < .001) or HPV vaccines (76%, p < .001) with OHCPs compared to those who were unvaccinated against COVID-19. African American/Black patients were less comfortable discussing vaccines, irrespective of vaccination status. CONCLUSIONS: OHCP can play a vital role in increasing the overall COVID-19 and HPV vaccination status of the public, as demonstrated by the high acceptance of dental involvement in both vaccine campaigns. Racial disparity in vaccination attitude is a public health challenge that needs to be addressed.


Subject(s)
COVID-19 , Papillomavirus Infections , Young Adult , Humans , COVID-19 Vaccines/therapeutic use , Papillomavirus Infections/prevention & control , Cross-Sectional Studies , Health Knowledge, Attitudes, Practice , Health Personnel , Vaccination , COVID-19/epidemiology , COVID-19/prevention & control
2.
Oncologist ; 24(8): 1013-1021, 2019 08.
Article in English | MEDLINE | ID: mdl-31088979

ABSTRACT

Safe use of immune checkpoint blockade in patients with cancer and autoimmune disorders requires a better understanding of the pathophysiology of immunologic activation. We describe the immune correlates of reactivation of granulomatosis with polyangiitis (GPA)-an antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis-in a patient with metastatic urothelial carcinoma treated with pembrolizumab. After PD-1 blockade, an inflammatory pulmonary nodule demonstrated a granulomatous, CD4+ T-cell infiltrate, correlating with increased CD4+ and CD8+ naïve memory cells in the peripheral blood without changes in other immune checkpoint receptors. Placed within the context of the existing literature on GPA and disease control, our findings suggest a key role for PD-1 in GPA self-tolerance and that selective strategies for immunotherapy may be needed in patients with certain autoimmune disorders. We further summarize the current literature regarding reactivation of autoimmune disorders in patients undergoing immune checkpoint blockade, as well as potential immunosuppressive strategies to minimize the risks of further vasculitic reactivation upon rechallenge with anti-PD-1 blockade. KEY POINTS: Nonspecific imaging findings in patients with cancer and rheumatological disorders may require biopsy to distinguish underlying pathology.Patients with rheumatologic disorders have increased risk of reactivation with PD-(L)1 immune checkpoint blockade, requiring assessment of disease status before starting treatment.Further study is needed to evaluate the efficacy of treatment regimens in preventing and controlling disease reactivation.


Subject(s)
Antibodies, Monoclonal, Humanized/adverse effects , Carcinoma, Transitional Cell/diagnosis , Granulomatosis with Polyangiitis/diagnosis , Neoplasm Recurrence, Local/diagnosis , Urinary Bladder Neoplasms/diagnosis , Adrenalectomy , Carcinoma, Transitional Cell/drug therapy , Carcinoma, Transitional Cell/immunology , Chemoradiotherapy, Adjuvant/adverse effects , Chemoradiotherapy, Adjuvant/methods , Cystectomy , Diagnosis, Differential , Granulomatosis with Polyangiitis/chemically induced , Granulomatosis with Polyangiitis/immunology , Humans , Male , Middle Aged , Multiple Endocrine Neoplasia Type 2a/immunology , Multiple Endocrine Neoplasia Type 2a/therapy , Neoplasm Recurrence, Local/drug therapy , Neoplasm Recurrence, Local/immunology , Nephroureterectomy , Programmed Cell Death 1 Receptor/antagonists & inhibitors , Programmed Cell Death 1 Receptor/immunology , Prostatectomy , Symptom Flare Up , Urinary Bladder Neoplasms/drug therapy , Urinary Bladder Neoplasms/immunology
3.
Cell Tissue Bank ; 19(4): 783-790, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30377864

ABSTRACT

Peripheral blood mononuclear cells (PBMCs) are essential to the study of autoimmune, infectious, parasitic diseases, and cancer. In the rapidly growing field of cancer immunology, cellular phenotyping provides critical information about patient responses to treatments and treatment efficacies. Notably, the evaluation of T cell based therapies relies on the isolation of highly viable CD3+ T cell, CD4+ Helper T cell, and CD8+ Cytotoxic T cell populations before and during patient treatments. Cryopreservation of PBMC populations allows researchers to thaw and characterize clinical samples by flow cytometry, mass cytometry, sequencing, etc. in a high-throughput manner and in batches. Therefore, it is important to separate and bank an abundance of robust circulating immune cells. Here, we report our internal protocols for the high-quality separation, banking, and thawing of clinically relevant PBMC populations. We present quality control data from 11 melanoma patients and characterize their CD3+, CD4+, and CD8+ T cells by 4-color flow cytometry.


Subject(s)
Biological Specimen Banks/standards , Cell Separation/methods , Leukocytes, Mononuclear/pathology , Melanoma/blood , Melanoma/pathology , Quality Control , Cell Count , Cell Survival , Humans , Immunophenotyping , Neoplasm Staging
SELECTION OF CITATIONS
SEARCH DETAIL
...